Get the Stockscreener App
49.79
1.39%
-0.70
After Hours:
49.84
0.05
+0.10%
Grail Inc stock is traded at $49.79, with a volume of 564.17K.
It is down -1.39% in the last 24 hours and up +15.63% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
See More
Previous Close:
$50.49
Open:
$50.85
24h Volume:
564.17K
Relative Volume:
0.45
Market Cap:
$2.04B
Revenue:
$147.17M
Net Income/Loss:
$-408.35M
P/E Ratio:
-4.454
EPS:
-11.1787
Net Cash Flow:
$-299.92M
1W Performance:
-1.95%
1M Performance:
+15.63%
6M Performance:
-34.07%
1Y Performance:
+91.98%
1-Day Range:
$49.00
$51.81
1-Week Range:
$44.06
$51.81
52-Week Range:
$25.12
$118.84
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
(833) 694-2553
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
49.79 | 2.07B | 147.17M | -408.35M | -299.92M | -11.18 |
TMO
Thermo Fisher Scientific Inc
|
531.67 | 195.93B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.14 | 140.56B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
580.76 | 46.39B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
119.77 | 34.02B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
326.20 | 32.49B | 3.17B | 642.63M | 516.49M | 10.77 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Mizuho | Neutral |
| Mar-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-19-26 | Initiated | TD Cowen | Hold |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-25 | Initiated | Canaccord Genuity | Buy |
| Nov-27-24 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
View All
Grail Inc Stock (GRAL) Latest News
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES - PR Newswire
(GRAL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages GRAIL, Inc. (GRAL) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2026-04-14 | Bronstein, Gewirtz & Grossman, LLC Encourages GRAIL, Inc. (GRAL) Stockholders to Inquire about Securities Investigation | NDAQ:GRAL | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GRAIL, Inc. (GRAL) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Mizuho Securities Maintains Grail(GRAL.US) With Hold Rating, Maintains Target Price $58 - Moomoo
GRAIL partners with Epic to broaden Galleri test access across US - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating GRAIL, Inc. (GRAL) And Encourages Stockholders to Connect - ACCESS Newswire
Key Study of Grail’s Cancer Detection Test Fails in Setback for Company - vocal.media
Mizuho initiates coverage of GRAIL (GRAL) with neutral recommendation - MSN
Piper Sandler initiates coverage of GRAIL (GRAL) with neutral recommendation - MSN
GRAIL, Inc. (GRAL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
GRAIL rated new Neural at Mizuho and Piper after study setback - Seeking Alpha
This WhiteFiber Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
Mizuho initiates Grail stock coverage with neutral rating on MCED outlook - Investing.com
Mizuho initiates Grail stock coverage with neutral rating on MCED outlook By Investing.com - Investing.com South Africa
Piper Sandler initiates Grail stock coverage with neutral rating By Investing.com - Investing.com South Africa
Piper Sandler initiates Grail stock coverage with neutral rating - Investing.com UK
Junction Collaborates with GRAIL to Power Scalable Access to the Galleri® Multi-Cancer Early Detection Test - BioSpace
Grail Insider Sold Shares Worth $2,286,526, According to a Recent SEC Filing - marketscreener.com
Grail Insider Sold Shares Worth $3,078,169, According to a Recent SEC Filing - marketscreener.com
Top GRAIL Inc. Executives Quietly Unload a Massive Block of Shares - TipRanks
GRAIL President Joshua Ofman Sells $3 Million in Stock - National Today
Ofman, Grail Inc. president, sells $3.07 million in shares By Investing.com - Investing.com Canada
Grail CEO Ragusa sells $6.1m in company stock - Investing.com UK
Grail CEO Ragusa sells $6.1m in company stock By Investing.com - Investing.com Canada
Ofman, Grail Inc. president, sells $3.07 million in shares - Investing.com
GRAIL (GRAL) CFO auto-sells 45,806 shares to cover tax obligations - Stock Titan
Tax sell-to-cover by GRAIL (GRAL) CEO on 123,502 shares - Stock Titan
GRAIL (GRAL) president’s Form 4 shows 61,665 shares sold to cover taxes - Stock Titan
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia - samsung.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GRAIL, Inc. (GRAL) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
GRAIL Inc (GRAL) Trading Down 3.54% on Apr 9 - GuruFocus
The tension at the heart of new healthcare tech - Business Insider
Multi-Cancer Early Detection Testing Market to Reach USD 7.52 - openPR.com
GRAIL Collaborates With Epic to Expand Availability of Galleri Test Nationwide - Bitget
GRAIL Partners With Epic to Broaden Galleri Test Access Across US - Yahoo Finance
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Grail, Epic Plan Galleri Test Integration For 450 Health Systems - Benzinga
GRAIL: NHS-Galleri Trial Results Are A Foul Ball, Not A Strikeout (NASDAQ:GRAL) - Seeking Alpha
GRAIL Partners with Epic to Expand Access to Galleri Multi-Cancer Early Detection Test - National Today
GRAIL integrates Galleri cancer test into Epic health records By Investing.com - Investing.com Australia
GRAIL integrates Galleri cancer test into Epic health records - Investing.com
GRAIL, Inc. Announces Integration of Galleri Test into Epic Electronic Health Record Platform - marketscreener.com
Why Grail Inc. Shares Are Sliding Again - TipRanks
GRAIL Announces Integration of the Galleri Test into Epic Electronic Health Record Platform to Expand Access Nationwide - Bitget
Grail updates 2025 cash burn guidance to $310M amid rising Galleri test adoption and expanded partnerships - MSN
[144] GRAIL, Inc. SEC Filing - Stock Titan
Director Ragusa reports multiple GRAL stock sales and RSU vesting (GRAL) - Stock Titan
GRAIL (NASDAQ:GRAL) Shares Down 4%Here's Why - MarketBeat
Why Grail’s Stock Keeps Sinking Despite New Deals - TipRanks
Grail Inc Stock (GRAL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.41%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):